Trial Profile
A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN).
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs AZD 1386 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms AVANT
- Sponsors AstraZeneca
- 30 Jul 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 24 Mar 2012 This trial is recruiting in France and discontinued in United Kingdon and Denmark.
- 01 Oct 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.